The Corona-related boom in the biotech business has even accelerated the upswing compared to previous years.
Frankfurt Changes in leadership are often accompanied by breaks. There can be no talk of this at the Darmstadt-based Merck Group. The new CEO, Belén Garijo, is demonstrating continuity with her first annual financial statements as CEO. She also has no reason for major course changes: Merck is in an unbroken upward trend.
The corona-related boom in the biotech business has even accelerated the upswing compared to previous years and should also ensure solid growth in 2022.
At the Annual General Meeting on Friday, Garijo can present Merck’s shareholders with a group that – despite all the political crises – is in good shape and in 2021 has achieved the highest operating income and cash flows in its more than 350-year history.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue